Nigerian startup Syndicate Bio partners NICRAT to launch cancer genome project
- Strategic partnership between Syndicate Bio and NICRAT to launch the Cancer Genome Nigeria project.
- Study aims to bridge cancer disparity gaps and study prevalent cancers across Nigeria.
- Syndicate Bio plans to deepen local precision medicine impact and generate valuable datasets.
The partnership between Syndicate Bio and NICRAT to launch the Cancer Genome Nigeria project is a significant step towards addressing cancer diagnosis and treatment in Nigeria. By studying the most prevalent cancers across the country, Syndicate Bio aims to bridge the gap in cancer care and improve treatment outcomes. This initiative has the potential to not only benefit patients in Nigeria but also contribute to global cancer research and precision medicine.
